McKesson Co. (NYSE:MCK) CEO Brian S. Tyler Sells 8,961 Shares

McKesson Co. (NYSE:MCK) CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total value of $5,382,514.26. Following the completion of the sale, the chief executive officer now owns 69,625 shares in the company, valued at approximately $41,820,952.50. This trade represents a 11.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

McKesson Price Performance

MCK stock opened at $603.68 on Friday. The stock has a market capitalization of $75.66 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 1.28 and a beta of 0.52. The business’s fifty day moving average price is $588.60 and its two-hundred day moving average price is $562.48. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $637.51.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Research analysts expect that McKesson Co. will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.47%. The ex-dividend date is Monday, March 3rd. McKesson’s dividend payout ratio (DPR) is currently 13.00%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Citigroup dropped their price target on McKesson from $713.00 to $677.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and increased their price target for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Bank of America dropped their price target on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus price target of $645.79.

Institutional Trading of McKesson

Large investors have recently modified their holdings of the stock. Millstone Evans Group LLC acquired a new stake in shares of McKesson during the 4th quarter worth $28,000. Synergy Asset Management LLC acquired a new stake in shares of McKesson during the 4th quarter worth $32,000. MidAtlantic Capital Management Inc. acquired a new stake in McKesson in the third quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in McKesson in the fourth quarter valued at about $33,000. Finally, Atala Financial Inc acquired a new stake in McKesson in the fourth quarter valued at about $34,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.